BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Belinostat readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Belinostat\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05627245-3412@assetmemo.bio
DTSTAMP:20261121T004114Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Belinostat: Phase 1 readout est. (NCT05627245)
DESCRIPTION:Belinostat\, phase 1.\nStudy: Testing the Safety of the Anti-ca
 ncer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Hav
 e Resisted Treatment\nEstimated primary completion: 1 June 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/belinostat#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05627245
URL:https://assetmemo.bio/drug/belinostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06406465-3412@assetmemo.bio
DTSTAMP:20261121T004114Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Belinostat: Phase 2 readout est. (NCT06406465)
DESCRIPTION:Belinostat\, phase 2.\nStudy: A UGT1A1 Genotype-Directed Study 
 of Belinostat Pharmacokinetics and Toxicity\nEstimated primary completion:
  30 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/belino
 stat#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06406465
URL:https://assetmemo.bio/drug/belinostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07691450-3412@assetmemo.bio
DTSTAMP:20261121T004114Z
DTSTART;VALUE=DATE:20291124
DTEND;VALUE=DATE:20291125
SUMMARY:Belinostat: Phase 1 readout est. (NCT07691450)
DESCRIPTION:Belinostat\, phase 1\, Peripheral T-Cell Lymphoma.\nStudy: Beli
 nostat in Combination With Azacitidine or Pralatrexate for the Treatment o
 f Relapse or Refractory T-cell Lymphoma\nEstimated primary completion: 24 
 November 2029. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/belino
 stat#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07691450
URL:https://assetmemo.bio/drug/belinostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06072131-3412@assetmemo.bio
DTSTAMP:20261121T004114Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Belinostat: Phase 3 readout est. (NCT06072131)
DESCRIPTION:Belinostat\, phase 3\, Peripheral T-Cell Lymphoma.\nStudy: To E
 valuate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP
  Alone in PTCL\nEstimated primary completion: July 2030. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/belinostat#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06072131
URL:https://assetmemo.bio/drug/belinostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
